ArticlePharmacology research & perspectives2024

Disposition of orally administered atuliflapon, a novel 5-lipoxygenase-activating protein inhibitor in healthy participants.

Xue-Qing Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.